# From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

- Link: https://www.thailand-business-news.com/pr-news/from-asia-to-the-global-oncology-stage-gene-solutions-contributes-multi-omic-innovation-at-esmo-congress-2026
- Published: 2026-11-18T05:00:00+07:00
- Author: PR Newswire

MADRID, Nov. 18, 2026 /PRNewswire/ — [Gene Solutions](https://genesolutions.com/)
hosted its first Global Industry Satellite Symposium, sharing multi-omic liquid 
biopsy technologies and the clinical and real-world data generated in Asia with 
the international oncology community. The achievement reflects the company’s evolution
from an Asia-based genetic testing pioneer to a globally engaged innovator of cell-
free DNA technologies spanning cancer screening, precision oncology, and functional
applications.

[⌊From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic 
Innovation at ESMO Congress 2026⌉⌊From Asia to the Global Oncology Stage: Gene Solutions
Contributes Multi-Omic Innovation at ESMO Congress 2026⌉[
From Asia to the Global
Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress
2026

ESMO Congress, one of the world’s leading oncology meetings, brought together more
than 40,000 participants from the global cancer community in Madrid in 2026 for 
the largest congress in ESMO’s history. The meeting provided a platform for scientific
exchange on advances in precision oncology.

The symposium, titled **"AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care
Continuum: From Technological Innovation to Scalable Clinical Implementation,"**
was attended at full capacity and convened internationally recognized experts, including
Prof. Umberto Malapelle, President of the International Society of Liquid Biopsy
and Professor at the University of Naples Federico II; Prof. Herbert Ho Fung Loong
of The Chinese University of Hong Kong; Prof. Aya El Helali of The University of
Hong Kong; Dr. Le Son Tran and Dr. Vien Le of the Medical Genetics Institute; and
Asst. Prof. Lucksamon Thamlikitkul of Siriraj Hospital, Mahidol University.  

The program reviewed multi-omic technologies and evidence from Asia, encompassing
both prospective clinical studies and real-world datasets. Sessions focused on challenges
and future directions in multi-cancer early detection, comprehensive genomic and
transcriptomic profiling, longitudinal ctDNA monitoring, and immune profiling as
well as functional patient-derived organoid models for evaluating treatment response
to support therapeutic decision-making.

Discussions across the presentations highlighted the value of integrating complementary
multi-omic approaches rather than relying on any single technology. Drawing on clinical
validation and real-world experience generated in Asia, Gene Solutions’ patient-
centered ecosystem was highlighted, connecting earlier detection, comprehensive 
genomic profiling, deeper biological and immune understanding, functional investigation
of treatment response, and longitudinal circulating tumor DNA monitoring around 
the needs of the same patient. The approach is intended to support more individualized
care while addressing the practical requirements of implementation across diverse
healthcare settings.

[⌊A patient-centered precision oncology ecosystem integrating earlier detection,
genomic profiling, multi-omic and immune insights, functional testing, and ctDNA
monitoring.⌉⌊A patient-centered precision oncology ecosystem integrating earlier
detection, genomic profiling, multi-omic and immune insights, functional testing,
and ctDNA monitoring.⌉[
A patient-centered precision oncology ecosystem integrating
earlier detection, genomic profiling, multi-omic and immune insights, functional
testing, and ctDNA monitoring.

Reflecting on the symposium discussions, Prof. Umberto Malapelle, President of the
International Society of Liquid Biopsy, emphasized the growing significance of multi-
cancer early detection:

"We discussed how the cancer-screening landscape is evolving and the potential role
of multi-cancer early detection. MCED assays represent one of the key weapons in
this battle against cancer. The technology is now available, promising data are 
emerging from different settings, and the next step is to generate the prospective
evidence needed to demonstrate clinical utility and support appropriate implementation."

Beyond early detection, symposium discussions also addressed how advanced molecular
technologies can be translated into routine cancer care across diverse healthcare
systems.

As Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong commented:

"Liquid biopsy can extend access to accurate genomic profiling in settings where
access to tissue-based testing may be limited. Combining liquid and tissue approaches
improves the completeness of molecular information available for monitoring, diagnosis,
and treatment selection, while generating data that may be relevant beyond the Asian
region."

The symposium also highlighted how precision oncology is evolving beyond genomic
alterations alone toward a more comprehensive understanding of disease biology.

Prof. Aya El Helali of The University of Hong Kong said:

"Precision oncology increasingly requires a multilayered understanding of disease,
integrating genomic, transcriptomic, epigenetic, proteomic, and immune-related information.
Bringing these insights together with functional models such as patient-derived 
organoids may help prioritize more individualized and evidence-driven treatment 
strategies."

Gene Solutions and the Medical Genetics Institute also contributed two posters presenting
real-world research from Southeast Asia on tissue and liquid-biopsy molecular profiling
and longitudinal ctDNA monitoring across multiple cancer types.

Beyond the scientific program, the company’s exhibition area facilitated discussions
with oncologists, molecular pathologists, translational researchers, laboratory 
leaders, healthcare institutions, pharma and industry colleagues throughout the 
conference.

Commenting on Gene Solutions’ participation at ESMO Congress 2026, Ida Deleskog 
Lindstroem, Global Medical Affairs Director at Gene Solutions**, **said:

"The discussions underscored both the progress made in applying multi-omic liquid
biopsy approaches in clinical practice and the remaining challenges in supporting
broader access. Our focus remains on advancing technologies that can deliver clinically
useful information — from earlier detection to treatment selection and disease monitoring—
across different healthcare settings."

For Gene Solutions, ESMO Congress 2026 represented more than a successful scientific
event. It marked an important step in a journey that began in Asia and continues
to grow through a commitment to innovations that support earlier cancer detection,
more precise treatment decisions, deeper biological understanding, and more effective
disease monitoring for patients worldwide.

Watch the faculty presentations and interviews, view the panel discussion, and explore
Gene Solutions’ scientific posters at: [https://www.genesolutions.com/inside-gene-solutions-esmo-2026-symposium-and-scientific-program-six-perspectives-across-the-cancer-care-continuum/](https://www.genesolutions.com/inside-gene-solutions-esmo-2026-symposium-and-scientific-program-six-perspectives-across-the-cancer-care-continuum/)

**About Gene Solutions**

[Gene Solutions](https://www.genesolutions.com/) is a global biotechnology company
advancing precision cell-free DNA solutions across cancer detection ([SPOT-MAS](https://www.genesolutions.com/our-solutions/spot-mas/)),
precision oncology ([K-TRACK, K-4CARE](https://www.genesolutions.com/our-solutions/k-track-k-4care/)),
and pregnancy care ([triSure](https://www.genesolutions.com/our-solutions/trisure/)).
By combining multi-omic science, data intelligence and a scalable technology platform,
Gene Solutions brings world-class genomics closer to clinicians and patients, expanding
access to clinically meaningful innovation around the world.

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026 ](https://en.prnasia.com/story/archive/5099850_AE99850_0?rand=184833)
